电子邮箱：qingzhang@xzhmu.edu.cn
张青，博士、教授、博士研究生导师。现任徐州医科大学研究生院院长、江苏省肿瘤生物治疗工程技术研究中心主任、江苏省肿瘤生物治疗工程实验室副主任。入选江苏省双创团队核心成员、333人才工程、六大人才高峰计划、青蓝工程中青年学术带头人称号。毕业于四川大学，美国北卡罗莱纳大学教堂山分校访问学者。主要从事肿瘤微环境和免疫治疗研究，发现治疗实体瘤效果优于4-1BB、CD28的CAR-T新型共刺激分子HVEM；揭示了肿瘤组织中棕榈酸（PA）抑制T细胞抗肿瘤免疫的分子机制；建立了CAR-T联合溶瘤腺病毒、肿瘤靶向药治疗实体瘤方案。主持国家自然科学基金、江苏省重点研发计划等课题10余项。以第一/通讯作者（含共同）在Cancer Immunol Res、Pharmacol Res、Cancer Lett、Cytokine Growth F R等杂志发表SCI论文27篇。现为中国抗癌协会合成生物医药专委会委员、江苏省免疫学会青年委员、江苏省移植与区域免疫专业委员会委员。
研究方向：肿瘤微环境与免疫治疗
代表论文：
1.Shishuo Sun, Heng Xu, Wanxin Zhao, Qihong Li, Yifan Yuan, Guopeng Zhang, Shuyu Li, Bixi Wang, Wei Zhang, Xiaoge Gao, Junnian Zheng,Qing Zhang*. PA suppresses antitumor immunity of T cells by disturbing mitochondrial activity through Akt/mTOR-mediated Ca2+ flux.Cancer Lett. 2024 Jan 28:581:216511.
2.Shishuo Sun, Chao Huang, Mengmeng Lu, Heng Xu, Yifan Yuan, Wanxin Zhao, Xiaolei Hu, Bixi Wang, Wei Zhang, Xiaoge Gao, Junnian Zheng, Lishan Su,Qing Zhang*. Herpes virus entry mediator costimulation signaling enhances CAR-T cell efficacy against solid tumors through metabolic reprogramming.Cancer Immunol Res. 2023, 11(4):515-529.
3.Chen Zhang, Lin Fang, Xueyan Wang, Sen Yuan, Wanjing Li, Weiping Tian, Jing Chen, Qi Zhang, Yuxin Zhang,Qing Zhang*, Junnian Zheng*. Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma.Mol Ther-Oncolytics. 2022, 24: 14-25.
4.Mengmeng Lu#, Xiaokang Zhang#, Bixi Wang, Shishuo Sun, Xiaoge Gao, Xiaohuan Wei, Xiaolei Hu, Chao Huang, Heng Xu, Wei Zhang, Zhen Li, Xinhui Feng, Junnian Zheng*,Qing Zhang*. Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer.Pharmacol Res. 2021, 174:105829.
5.Hongyan Liu, Shishuo Sun, Gang Wang, Mengmeng Lu, Xiaokang Zhang, Xiaohuan Wei, Xiaoge Gao, Chao Huang, Zhen Li, Junnian Zheng*,Qing Zhang*. Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity.Front Oncol.2021,11: 663517.
6.Li Huizhong,Ding Jiage, Lu Mengmeng, Liu Hongyan, Miao Yangna, Li Liantao, Wang Gang, Zheng Junnian, Pei Dongsheng,Zhang Qing*.CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.J Immunother.2020.43(1):16-28.
7.Qing Zhang, Jiage Ding, Shishuo Sun, Hongyan Liu, Mengmeng Lu, Xiaohuan Wei, Xiaoge Gao, Xiaokang Zhang, Qiang Fu, Junnian Zheng.Aktinhibition at the initial stage of CAR-T preparation enhances the CAR-positive expression rate, memory phenotype and in vivo efficacy.Am J CancerRes. 2019, 9(11):2379-2396.
8.Jinwu Chen*, Xiaojie Li*, Ling Li*, Ting Zhang*,Qing Zhang*(Co-first author),Fangming Wu, Diyue Wang, Hongze Hu, Changlin Tian, Dongsheng Liao, Liang Zhao, Danxia Song, Yongyun Zhao, Chuanfang Wu, Xu Song.Coagulation factors VII, IX and X are antibacterial proteins against drug-resistant Gram-negative bacteria.Cell Research. 2019. 29(9):711-724.
9.Qing Zhang, Hongyan Liu, Hanhan Wang, Mengmeng Lu,Yangna Miao, Jiage Ding, Huizhong Li, Xiaoge Gao, Shishuo Sun, Junnian Zheng.Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells.Am J CancerRes. 2019, 9(7):1382-1395.
10.Jinjing Xu, Kang Tian, Haixu Zhang, Liantao Li, Hongyan Liu, Jingjie Liu,QingZhang*，Junnian Zheng*.Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.Expert Review of Anticancer Therapy.2017, 17(12): 1099-1106.
